Introduction
The purpose of this ASCOT sub-study is to evaluate and improve the performance of existing absolute cardiovascular risk prediction techniques for a northern European population of high risk hypertensive men and women. Many guidelines for the management of hypertension and raised cholesterol now recommend therapeutic interventions based on an individuals absolute risk of disease rather than specific levels of blood pressure or cholesterol. 1 However the method by which cardiovascular risk is assessed is the subject of extensive debate. While it is widely accepted that clinicians intuitive estimates of risk are inaccurate, 2 the debate over which formal risk assessment tool should be recommended to clinicians, continues to thrive at international, national and regional levels. It is therefore of clinical and financial importance in Europe where patients are at high risk of cardiovascular disease, to ensure these tools accurately predict risk if recommended prescribing is to occur. The investigation proposed here takes advantage of data collected for the ASCOT study. ASCOT (Anglo-Scandinavian Cardiac Outcome Trial) aims to compare the impact of different antihypertensive regimes on fatal and nonfatal coronary heart disease and stroke. In addition it seeks to address whether hypertensive subjects with a total cholesterol р6.5 benefit from cholesterol lowering with 10 mg atorvastatin. It is of particular Correspondence: Professor Mark Caufield, Department of Clinical Pharmacology, St Bartholomew's and the Royal London School of Medicine and Dentistry, Charterhouse Square, London EC1M 5BQ, UK E-mail: m.j.caulfieldȰmds.qmw.ac.uk significance to this sub-study that the 18 000 subjects are selected to be at reasonably high risk of cardiovascular mortality and morbidity and both risk factors and outcomes are systematically documented. The study described here will analyse 18 000 cardiovascular risk profiles and known outcome data. This will provide a contribution to the management of essential hypertension by evaluating and improving the predictive performance of currently available cardiovascular risk assessment tools in a northern European high risk hypertensive population.
Background and rationale
Cardiovascular disease is one of the major causes of mortality and morbidity in Western industrialised countries and accounted for 40% of all deaths in the UK in 1990. 3 Epidemiological studies have indicated that many factors impact on an individual's likelihood of a cardiovascular disease event. 3, 4 Factors such as age, smoking, male sex, elevated cholesterol, presence of left ventricular hypertrophy (LVH) on electrocardiogram (ECG) and diabetes have all been linked to increasing cardiovascular risk. Much work has been done to determine the contributions each of these factors has on the overall risk of cardiovascular disease. The likelihood of an individual having a cardiovascular event over a given time period, usually specified as 5 or 10 years, is referred to as absolute cardiovascular risk. Many guidelines for the management of hypertension and raised cholesterol now recommend the use of absolute cardiovascular risk profiles to guide therapeutic decisions rather than thresholds of blood pressure or cholesterol. 1 This targets therapy at those who face the greatest risk of heart attack, stroke or death. The multi-factorial nature of cardiovascular disease and the interactions between risk factors make it difficult for clinicians to assess intuitively an individual's likelihood of developing disease. 2 This has led to many tools being developed to make the risk equations accessible for use in routine clinical practice (The Framingham Equation, The New Zealand Tables, The Sheffield Tables) . [4] [5] [6] Recent work comparing these tools has indicated variations in risk and this has led to criticism of the accuracy of some of these techniques. 7, 8 However the patient populations used to conduct the comparison studies were small (386 and 206 patients) and the patients were recruited from specialist lipid and hypertension clinics respectively. The population we are proposing to use in this ASCOT sub-study has three advantages. Firstly it takes advantage of one of the largest sources of risk and outcome data for a northern European hypertensive population (18 000 data sets). Secondly the majority of patients are drawn from General Practice rather than from specialist clinics. Thirdly there are significant cohorts from London, Leicester and Birmingham representing the ethnic diversity of the UK community. 
Objectives

Study methods/design
The ASCOT database, defined as the data recorded on each of 18 000 subjects randomised into the study at screening, randomisation and annual follow-up visits, has been made available to answer the objectives as outlined above.
A software tool will be developed to enable currently available cardiovascular risk assessment tools (The Framingham Equation, New Zealand Tables,  Sheffield Tables) to be applied to the data.
The ASCOT screening data will be used to compare the risk assessment tools. Experiments will be run to explore the impact of using the tools with dummy values for cholesterol components (HDL) and LVH to simulate lost or unavailable data when the equations are used in routine clinical practice. This is important because open access echocardiography and routine HDL cholesterol are not available to every patient in the UK.
At the end of the ASCOT study when outcome data is available, the tools predicted risk will compared to observed events to quantify their predictive performance.
Additional data is being collected to determine whether doctors can accurately assess patients risk of cardiovascular disease by intuitive methods. Doctors at St. Bartholomew's Regional ASCOT Centre are rating their patients' risk on a 5-point scale (low, mild, moderate, high, very high) at the time the patient is enrolled into the study. At this point the doctor has access to all the data used by the equations to assess risk, and has, in addition completed a physical examination of the patient. This will provide the basis to compare the doctors predicted risk with that of cardiovascular risk assessment tools and known outcome data.
Finally risk factor profiles of the cohort will be analysed to improve the predictive performance of currently available tools and increase their specificity to high risk hypertensive patients.
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Discussion
Current understanding of the relationships between different risk factors and the development of cardiovascular disease is based on large population studies. 3, 4 The Framingham study is widely acknowledged as one of the most important prospective observational studies in cardiovascular risk prediction due to its rigorous methodology, long follow-up period and the availability of data for both men and women. 4 The latest equations developed from the Framingham data were published in 1991 based on a population of 5573 individuals that had been followed for a period of 12 years. Risk factors considered in the equations included age, sex, systolic or diastolic blood pressure, total and HDL cholesterol, smoking, diabetes, LVH measured on ECG. These equations have been widely recommended to clinicians, 1 however there are several issues that restrict their use in routine clinical practice. Firstly two equations were published allowing clinicians to choose whether to use systolic and diastolic blood pressure. The American Heart Association recommended the use of systolic blood pressure as it was believed to be more accurately determined, had a wider range of values and was a stronger predictor of risk, particularly in the elderly. 4 However two equations leads to confusion for practitioners and further work is needed to compare their performance. Secondly a limited number of risk factors were used in the equations reducing their predictive capacity. The risk factors were chosen because they could be measured objectively and made independent contributions to the development of cardiovascular disease. However several important risk factors, including family history were not included. Finally while it is generally agreed that caution should be used when applying these equations to populations with different coronary heart disease incidence rates than the original Framingham population, there is little evidence of their applicability to different ethnic groups. 9 The study outlined in this proposal will address these issues by taking advantage of one of the largest sources of risk and outcome data, which represents the ethnic diversity of the northern European hypertensive population.
The Framingham equations have been used to develop other user-friendly tools to help clinicians assess their patient's cardiovascular risk without the need to apply complex mathematical formulae. The New Zealand Tables were published in 1993 by  Jackson. 5 A colour chart showed how the absolute risk of cardiovascular disease is affected by combinations of risk factors. Each square gives an indication of an individual's 10-year risk, Ͻ10%, 10-20%, 20-40%, Ͼ40%. The Framingham equation on which these tables are based has been demonstrated to be effective at separating out those individuals at low and high risk. Less evidence is available for assessing more subtle distinctions between the risk Journal of Human Hypertension stratification. 9 The ASCOT cohort, which has been selected to be at reasonably high risk (risk profiles ranging from Ͻ5% to Ͼ40%) will allow us to assess the relevance of detailed cardiovascular risk profiling.
The Sheffield Tables, also developed from the Framingham equations, were designed to help clinicians decide which of their patients required lipid lowering therapy as primary prevention. 6 A study by Durrington comparing different cardiovascular risk assessment tools suggested that the Sheffield Tables underestimated risk compared with the Framingham equations. 7 The observed differences were attributed to the use of dummy HDL values and the failure to take into account the association between low HDL and multiple risk factors for coronary heart disease. However the comparison study used a small population of patients referred to a specialist lipid clinic for whom the use of dummy HDL would be the least appropriate. 9 The ASCOT cohort provides a much larger patient population which have been drawn from General Practice rather than from specialist clinics and thus have a more representative range of risk factor profiles on which to base this analysis.
